Strasbourg, France — October 3, 2025 — Leads & Copy — Transgene (Euronext Paris: TNG) will present a poster at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) highlighting an in-depth analysis of the neoantigen-specific T cell response from the randomized Phase I trial of its individualized therapeutic cancer vaccine, TG4050. SITC will take place November 5 to 9, 2025, in National Harbor, Maryland, USA.
The poster, titled “Profiling of the neoantigen-specific T cell response after adjuvant TG4050 individualized therapeutic vaccination in a randomized Phase 1 trial for locally advanced resected HPV negative HNSCC,” will be presented on November 8, 2025. The abstract will be available on the SITC website on November 4, 2025, at 9 a.m. ET. The poster and abstract number is 502. C. Le Tourneau is listed as the author.
TG4050, developed for solid tumors, is based on Transgene’s myvac® technology and powered by NEC’s AI expertise. It is being evaluated in a randomized multicenter Phase I/II clinical trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers (NCT04183166).
Transgene previously presented at the ASCO conference in June 2025, that all patients from Phase I who received TG4050 remained disease-free after a minimum of 2-year follow-up, comparing favorably to the observational arm which saw 3 out of 16 patients relapse during the same time period.
Transgene and NEC are continuing the joint development of TG4050 in this indication with a Phase II extension of the trial, which is currently enrolling patients.
Contacts:
Media: Caroline Tosch, Corporate and Scientific Communications Manager, +33 (0)3 68 33 27 38, communication@transgene.fr. Frazer Hall/Sylvie Berrebi, MEDiSTRAVA, + 44 (0)203 928 6900, transgene@medistrava.com.
Investors & Analysts: Lucie Larguier, Chief Financial Officer (CFO). Nadege Bartoli, Investor Relations Analyst and Financial Communications Officer, +33 (0)3 88 27 91 00/03, investorrelations@transgene.fr.
Source: Transgene
